About Alessa Therapeutics
Alessa Therapeutics is a company based in San Francisco (United States) founded in 2018 by Pamela Munster and Scott Thomas. Alessa Therapeutics has raised $43.64 million across 5 funding rounds from investors including Johnson & Johnson, HHS and Mission BioCapital. Alessa Therapeutics offers products and services including Enolen, Biolen + RT, and Biolen-PC. Alessa Therapeutics operates in a competitive market with competitors including Vensica Medical and Taris Biomedical, among others.
- Headquarter San Francisco, United States
- Founders Pamela Munster, Scott Thomas
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alessa Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$43.64 M (USD)
in 5 rounds
-
Latest Funding Round
$25.38 M (USD), Series A
Apr 18, 2025
-
Investors
Johnson & Johnson
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alessa Therapeutics
Alessa Therapeutics offers a comprehensive portfolio of products and services, including Enolen, Biolen + RT, and Biolen-PC.
Implantable system for localized anti-androgen therapy in prostate cancer.
System for sustained drug administration to prostate tumors.
Implant for prostate cancer treatment without systemic exposure.
People of Alessa Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Alessa Therapeutics
Alessa Therapeutics has successfully raised a total of $43.64M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $25.38 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alessa Therapeutics
Alessa Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, HHS and Mission BioCapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life science startups are made by Mission BioCapital.
|
Locked | Locked | Locked | |
|
Healthcare solutions are provided by Johnson & Johnson globally.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Alessa Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alessa Therapeutics
Investment portfolio details for Alessa Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alessa Therapeutics
Detailed financials for Alessa Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alessa Therapeutics Comparisons
Peer comparison for Alessa Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alessa Therapeutics
Alessa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vensica Medical and Taris Biomedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Catheters for ultrasound-guided drug delivery to the bladder are developed.
|
|
| Locked | Locked | Locked |
Drug delivery technology for genitourinary diseases is developed.
|
Detailed competitors of Alessa Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alessa Therapeutics
Complete news archive for Alessa Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alessa Therapeutics
Alessa Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alessa Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
John Maroney is the current CEO of Alessa Therapeutics.
Alessa Therapeutics is a funded company, having raised a total of $43.64M across 5 funding rounds to date.
Alessa Therapeutics was founded in 2018 in San Francisco, United States, within the biotechnology sector. Implantable drug-eluting systems are created for localized administration of anti-androgen therapies to prostate tumors, enabling sustained release without systemic exposure. Clinical studies are conducted to assess efficacy and safety for treating prostate cancer and benign prostatic hyperplasia. Operations focus on minimally invasive delivery approaches.
Alessa Therapeutics's top competitors include Vensica Medical and Taris Biomedical.
Alessa Therapeutics offers Enolen, Biolen + RT, and Biolen-PC.
Alessa Therapeutics has 3 investors. Key investors include Johnson & Johnson, HHS, and Mission BioCapital.